Insider Cluster (2 insiders) ·Filed Apr 10, 2026

KYMR

Kymera Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed5mo ago
Insider cluster: 2 insiders, $549K total
Actionable Insight • Neutral

The level of selling is minimal relative to company size and appears routine; no material negative signal is evident. Traders should monitor for further selling patterns, especially among C-suite executives, but this cluster alone does not suggest urgency or distress.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
KYMR ▲ +40.20% at T+60d
NEUTRAL call ✓ call won +40.20% · α vs SPY +29.87% · entry $85.05 → $119.24
Entry anchored
Apr 9, 03:59 PM ET
via exchange tick
T+1d
+4.09%
call +4.09% · α +3.12%
$88.53
settled 6mo ago
T+5d
+3.13%
call +3.13% · α -1.38%
$87.71
settled 6mo ago
T+20d
-0.49%
call -0.49% · α -9.02%
$84.63
settled 5mo ago
T+60d
+40.20%
call +40.20% · α +29.87%
$119.24
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Two corporate insiders at Kymera Therapeutics sold shares in the past week, including Director Booth Bruce selling 4,159 shares for $374,185 and Chief Business Officer Noah Goodman selling 2,000 shares for $174,700. The total open-market sales amount to $549,000, representing 0.0075% of the company's $7.3B market cap. Most transactions were non-cash derivative exercises with no economic impact.

Key Financial Metrics

Direction
selling
Total Value
$548.9K
Insiders
2

Key Facts

  • Director Booth Bruce sold 4,159 shares for $374,185 on 2026-04-14 and also exercised 10,518 derivative shares (non-cash) across multiple transactions.
  • Chief Business Officer Noah Goodman sold 2,000 shares for $174,700 on 2026-04-10.
  • Total open-market sales in the cluster: $549,000.
  • Total value represents 0.0075% of Kymera's $7.3B market cap.
  • Multiple derivative exercises and tax-related transactions (codes M, F) are non-cash events with no direct financial impact.

Financial Impact

$549,000 in open-market sales (0.0075% of market cap)

insider ownershipshare count

Risk Factors

  • Continued insider selling could erode confidence if volume increases.
  • Non-cash derivative exercises may signal upcoming selling pressure if shares are now held outright.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-KYMR-1776377848802
30 reports for KYMR
Performance horizon
67% Hit rate 8 of 12 directional calls best @ T+60▲ +60.99%Jun 8, 2026
Filters
Rows
Reports for KYMR — sortable, filterable
TypeNow
Aug 5, 2026
8w ago
8-K
BULLISH ★ 6/10
$105.48 $118.63▲ +12.47%▲ +13.07%$107.39 (+1.81%)
Jul 8, 2026
12w ago
Insider Cluster
BEARISH ★ 5/10
$114.16 $105.48▲ +7.60%▲ +10.88%$107.39 (+5.93%)
Jul 2, 2026
13w ago
Insider Cluster
BEARISH ★ 6/10
$113.51 $107.01▲ +5.73%▲ +5.31%$107.39 (+5.39%)
Jul 2, 2026
13w ago
Insider Cluster
BEARISH ★ 5/10
$113.51 $107.01▲ +5.73%▲ +5.31%$107.39 (+5.39%)
Jun 30, 2026
13w ago
144
BEARISH ★ 4/10
$114.20 $105.25▲ +7.84%▲ +5.65%$107.39 (+5.96%)
Jun 29, 2026
13w ago
144
NEUTRAL ★ 4/10
$114.67 $110.05▼ −4.03%▼ −3.00%$107.39 (−6.35%)
Jun 26, 2026
13w ago
Insider Cluster
BEARISH ★ 6/10
$109.32 $110.57▼ −1.14%▼ −1.42%$107.39 (+1.77%)
Jun 26, 2026
13w ago
144
BEARISH ★ 6/10
$109.32 $110.57▼ −1.14%▼ −1.42%$107.39 (+1.77%)
Jun 26, 2026
14w ago
144
BEARISH ★ 6/10
$109.32 $110.57▼ −1.14%▼ −1.42%$107.39 (+1.77%)
Jun 24, 2026
14w ago
144
NEUTRAL ★ 2/10
$116.46 $110.38▼ −5.22%▼ −5.75%$107.39 (−7.79%)
Showing 10 of 30

US Market Status

Market Closed — Opens Mon (64h 21m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Apr 16, 2026